The debate supports carrying forward APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology only if a proximal endpoint changes before the late outcome. The decisive validation path is: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
2 citations0 with PMIDValidation: 0%1 supporting / 1 opposing
✓For(1)
No supporting evidence
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
APOE genotype affects many cell types, so target c…
Opposing
GENE
AD-MASTER-PLAN-…
-
-
-
-
-
Legacy Card View — expandable citation cards
✓ Supporting Evidence
1
Preregistered claim: APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting APOE4 to …▼
Preregistered claim: APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting APOE4 to APOE3 reduces amyloid and restores synaptic function
AD-MASTER-PLAN-APOE-20260428030754
✗ Opposing Evidence
1
APOE genotype affects many cell types, so target conversion could rescue biomarkers without proving synaptic c…▼
APOE genotype affects many cell types, so target conversion could rescue biomarkers without proving synaptic causality
AD-MASTER-PLAN-APOE-20260428030754
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-28 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Theorist position for analysis AD-MASTER-PLAN-APOE-20260428030754: AD Master Plan preregistration: APOE
Context: Preregistered claim: APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting APOE4 to APOE3 reduces amyloid and restores synaptic function
Primary claim: APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this AD master-plan preregistration, th
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic critique for analysis AD-MASTER-PLAN-APOE-20260428030754: AD Master Plan preregistration: APOE
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: APOE genotype affects many cell types, so target conversion could rescue biomarkers without proving synaptic causality.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across A
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain expert assessment for analysis AD-MASTER-PLAN-APOE-20260428030754: AD Master Plan preregistration: APOE
The practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence intervals, a notebook reproducibility badge, or a revised preregistration.
Feasibility is modera
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology requires proximal validation", "description": "The debate supports carrying forward APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology only if a proximal endpoint changes before the late outcome. The decisive validation path is: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts.", "target_gene": "APOE", "dimension_scores": {
Price History
No price history recorded yet
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0
Clinical Trials (0)
No clinical trials data available
📚 Cited Papers (0)
No linked papers yet
📅 Citation Freshness Audit
Freshness score = exp(-age×ln2/5): halves every 5 years.
Green >0.6,
Amber 0.3–0.6,
Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.